nur für Forschungszwecke
Kat.-Nr.S8059
| Verwandte Ziele | Bcl-2 Caspase PD-1/PD-L1 Ferroptosis p53 Apoptosis related Synthetic Lethality STAT TNF-alpha Ras |
|---|---|
| Weitere MDM2/MDMX Inhibitoren | Nutlin-3 RG-7112 Brigimadlin Idasanutlin (RG7388) SAR405838 NSC 207895 NVP-CGM097 Siremadlin (HDM201) Nutlin-3b MX69 |
| Zelllinien | Assay-Typ | Konzentration | Inkubationszeit | Formulierung | Aktivitätsbeschreibung | PMID |
|---|---|---|---|---|---|---|
| MV-4-11 | Growth Inhibition Assay | IC50=0.61237 μM | SANGER | |||
| H4 | Growth Inhibition Assay | IC50=0.6628 μM | SANGER | |||
| PA-1 | Growth Inhibition Assay | IC50=0.87096 μM | SANGER | |||
| NKM-1 | Growth Inhibition Assay | IC50=1.04931 μM | SANGER | |||
| NEC8 | Growth Inhibition Assay | IC50=1.21572 μM | SANGER | |||
| EoL-1-cell | Growth Inhibition Assay | IC50=1.26701 μM | SANGER | |||
| K5 | Growth Inhibition Assay | IC50=1.42072 μM | SANGER | |||
| QIMR-WIL | Growth Inhibition Assay | IC50=1.60854 μM | SANGER | |||
| MOLT-16 | Growth Inhibition Assay | IC50=1.78604 μM | SANGER | |||
| CHP-212 | Growth Inhibition Assay | IC50=1.81369 μM | SANGER | |||
| CTB-1 | Growth Inhibition Assay | IC50=2.02246 μM | SANGER | |||
| MOLT-4 | Growth Inhibition Assay | IC50=2.32853 μM | SANGER | |||
| A101D | Growth Inhibition Assay | IC50=2.3501 μM | SANGER | |||
| DOHH-2 | Growth Inhibition Assay | IC50=2.42279 μM | SANGER | |||
| ES4 | Growth Inhibition Assay | IC50=2.43155 μM | SANGER | |||
| SW780 | Growth Inhibition Assay | IC50=2.50883 μM | SANGER | |||
| VA-ES-BJ | Growth Inhibition Assay | IC50=2.5411 μM | SANGER | |||
| RPMI-8866 | Growth Inhibition Assay | IC50=2.56214 μM | SANGER | |||
| ML-2 | Growth Inhibition Assay | IC50=2.56576 μM | SANGER | |||
| MSTO-211H | Growth Inhibition Assay | IC50=2.57451 μM | SANGER | |||
| JVM-3 | Growth Inhibition Assay | IC50=2.59324 μM | SANGER | |||
| A3-KAW | Growth Inhibition Assay | IC50=2.61818 μM | SANGER | |||
| DK-MG | Growth Inhibition Assay | IC50=2.62471 μM | SANGER | |||
| LNCaP-Clone-FGC | Growth Inhibition Assay | IC50=2.64318 μM | SANGER | |||
| HT-144 | Growth Inhibition Assay | IC50=2.64577 μM | SANGER | |||
| NB69 | Growth Inhibition Assay | IC50=2.65334 μM | SANGER | |||
| A172 | Growth Inhibition Assay | IC50=2.67588 μM | SANGER | |||
| RS4-11 | Growth Inhibition Assay | IC50=2.72407 μM | SANGER | |||
| DU-4475 | Growth Inhibition Assay | IC50=2.79502 μM | SANGER | |||
| SJSA-1 | Growth Inhibition Assay | IC50=2.82556 μM | SANGER | |||
| BV-173 | Growth Inhibition Assay | IC50=2.84439 μM | SANGER | |||
| U-2-OS | Growth Inhibition Assay | IC50=2.9107 μM | SANGER | |||
| CHP-134 | Growth Inhibition Assay | IC50=2.93882 μM | SANGER | |||
| D-502MG | Growth Inhibition Assay | IC50=2.97154 μM | SANGER | |||
| KS-1 | Growth Inhibition Assay | IC50=3.01623 μM | SANGER | |||
| A204 | Growth Inhibition Assay | IC50=3.05588 μM | SANGER | |||
| KGN | Growth Inhibition Assay | IC50=3.08496 μM | SANGER | |||
| NCI-H292 | Growth Inhibition Assay | IC50=3.12028 μM | SANGER | |||
| CAKI-1 | Growth Inhibition Assay | IC50=3.12694 μM | SANGER | |||
| C2BBe1 | Growth Inhibition Assay | IC50=3.17026 μM | SANGER | |||
| NB10 | Growth Inhibition Assay | IC50=3.20966 μM | SANGER | |||
| MHH-NB-11 | Growth Inhibition Assay | IC50=3.26827 μM | SANGER | |||
| NCI-SNU-1 | Growth Inhibition Assay | IC50=3.27843 μM | SANGER | |||
| HCT-116 | Growth Inhibition Assay | IC50=3.30335 μM | SANGER | |||
| G-401 | Growth Inhibition Assay | IC50=3.36322 μM | SANGER | |||
| MN-60 | Growth Inhibition Assay | IC50=3.44092 μM | SANGER | |||
| SW982 | Growth Inhibition Assay | IC50=3.50848 μM | SANGER | |||
| RKO | Growth Inhibition Assay | IC50=3.53936 μM | SANGER | |||
| D-283MED | Growth Inhibition Assay | IC50=3.57986 μM | SANGER | |||
| LB996-RCC | Growth Inhibition Assay | IC50=3.62558 μM | SANGER | |||
| A549 | Growth Inhibition Assay | IC50=3.63552 μM | SANGER | |||
| LB2241-RCC | Growth Inhibition Assay | IC50=3.65708 μM | SANGER | |||
| SK-HEP-1 | Growth Inhibition Assay | IC50=3.74297 μM | SANGER | |||
| G-402 | Growth Inhibition Assay | IC50=3.80832 μM | SANGER | |||
| GOTO | Growth Inhibition Assay | IC50=3.84333 μM | SANGER | |||
| LOXIMVI | Growth Inhibition Assay | IC50=3.85675 μM | SANGER | |||
| NH-12 | Growth Inhibition Assay | IC50=4.01959 μM | SANGER | |||
| CTV-1 | Growth Inhibition Assay | IC50=4.07973 μM | SANGER | |||
| CP50-MEL-B | Growth Inhibition Assay | IC50=4.24392 μM | SANGER | |||
| RH-18 | Growth Inhibition Assay | IC50=4.27706 μM | SANGER | |||
| NB17 | Growth Inhibition Assay | IC50=4.31768 μM | SANGER | |||
| A375 | Growth Inhibition Assay | IC50=4.33524 μM | SANGER | |||
| IST-MES1 | Growth Inhibition Assay | IC50=4.41411 μM | SANGER | |||
| MZ2-MEL | Growth Inhibition Assay | IC50=4.50155 μM | SANGER | |||
| CAL-54 | Growth Inhibition Assay | IC50=4.53019 μM | SANGER | |||
| NCI-H28 | Growth Inhibition Assay | IC50=4.62717 μM | SANGER | |||
| D-247MG | Growth Inhibition Assay | IC50=4.75072 μM | SANGER | |||
| NCI-H460 | Growth Inhibition Assay | IC50=4.91127 μM | SANGER | |||
| MCF7 | Growth Inhibition Assay | IC50=5.44244 μM | SANGER | |||
| 697 | Growth Inhibition Assay | IC50=5.4455 μM | SANGER | |||
| ONS-76 | Growth Inhibition Assay | IC50=5.57009 μM | SANGER | |||
| C32 | Growth Inhibition Assay | IC50=5.60029 μM | SANGER | |||
| OS-RC-2 | Growth Inhibition Assay | IC50=5.73887 μM | SANGER | |||
| MEL-HO | Growth Inhibition Assay | IC50=5.85667 μM | SANGER | |||
| LoVo | Growth Inhibition Assay | IC50=6.01624 μM | SANGER | |||
| AGS | Growth Inhibition Assay | IC50=6.14828 μM | SANGER | |||
| GI-ME-N | Growth Inhibition Assay | IC50=6.22421 μM | SANGER | |||
| H-EMC-SS | Growth Inhibition Assay | IC50=6.386 μM | SANGER | |||
| RVH-421 | Growth Inhibition Assay | IC50=6.42428 μM | SANGER | |||
| SW954 | Growth Inhibition Assay | IC50=6.55572 μM | SANGER | |||
| NB5 | Growth Inhibition Assay | IC50=6.56183 μM | SANGER | |||
| NCI-H2122 | Growth Inhibition Assay | IC50=6.58793 μM | SANGER | |||
| AM-38 | Growth Inhibition Assay | IC50=6.75639 μM | SANGER | |||
| KNS-81-FD | Growth Inhibition Assay | IC50=6.76494 μM | SANGER | |||
| LS-513 | Growth Inhibition Assay | IC50=6.79026 μM | SANGER | |||
| A427 | Growth Inhibition Assay | IC50=6.87829 μM | SANGER | |||
| WM-115 | Growth Inhibition Assay | IC50=6.9323 μM | SANGER | |||
| COLO-829 | Growth Inhibition Assay | IC50=7.24188 μM | SANGER | |||
| NCI-H1650 | Growth Inhibition Assay | IC50=7.39228 μM | SANGER | |||
| NCI-H358 | Growth Inhibition Assay | IC50=7.44879 μM | SANGER | |||
| HT-1080 | Growth Inhibition Assay | IC50=7.48254 μM | SANGER | |||
| HCC2218 | Growth Inhibition Assay | IC50=7.6297 μM | SANGER | |||
| NCI-H661 | Growth Inhibition Assay | IC50=7.87069 μM | SANGER | |||
| KM-H2 | Growth Inhibition Assay | IC50=7.88694 μM | SANGER | |||
| RPMI-2650 | Growth Inhibition Assay | IC50=7.94414 μM | SANGER | |||
| NCI-H226 | Growth Inhibition Assay | IC50=8.21122 μM | SANGER | |||
| MKN45 | Growth Inhibition Assay | IC50=8.26602 μM | SANGER | |||
| D-392MG | Growth Inhibition Assay | IC50=8.52722 μM | SANGER | |||
| RCC10RGB | Growth Inhibition Assay | IC50=8.86695 μM | SANGER | |||
| CAL-51 | Growth Inhibition Assay | IC50=9.10251 μM | SANGER | |||
| COLO-678 | Growth Inhibition Assay | IC50=9.32811 μM | SANGER | |||
| SK-MEL-24 | Growth Inhibition Assay | IC50=9.55856 μM | SANGER | |||
| SK-MEL-30 | Growth Inhibition Assay | IC50=9.94476 μM | SANGER | |||
| MMAC-SF | Growth Inhibition Assay | IC50=10.3961 μM | SANGER | |||
| NTERA-S-cl-D1 | Growth Inhibition Assay | IC50=10.6508 μM | SANGER | |||
| NB12 | Growth Inhibition Assay | IC50=11.503 μM | SANGER | |||
| UACC-257 | Growth Inhibition Assay | IC50=11.8695 μM | SANGER | |||
| LAN-6 | Growth Inhibition Assay | IC50=11.9928 μM | SANGER | |||
| SW1573 | Growth Inhibition Assay | IC50=12.3086 μM | SANGER | |||
| NMC-G1 | Growth Inhibition Assay | IC50=12.4175 μM | SANGER | |||
| SHP-77 | Growth Inhibition Assay | IC50=12.5574 μM | SANGER | |||
| IGROV-1 | Growth Inhibition Assay | IC50=12.6573 μM | SANGER | |||
| 22RV1 | Growth Inhibition Assay | IC50=12.8059 μM | SANGER | |||
| SK-MEL-3 | Growth Inhibition Assay | IC50=13.3973 μM | SANGER | |||
| NCI-H1563 | Growth Inhibition Assay | IC50=13.4202 μM | SANGER | |||
| IGR-1 | Growth Inhibition Assay | IC50=14.0347 μM | SANGER | |||
| EW-3 | Growth Inhibition Assay | IC50=14.1639 μM | SANGER | |||
| JEG-3 | Growth Inhibition Assay | IC50=14.4953 μM | SANGER | |||
| ES3 | Growth Inhibition Assay | IC50=14.6562 μM | SANGER | |||
| MDA-MB-175-VII | Growth Inhibition Assay | IC50=14.7111 μM | SANGER | |||
| P30-OHK | Growth Inhibition Assay | IC50=15.0496 μM | SANGER | |||
| GP5d | Growth Inhibition Assay | IC50=15.1466 μM | SANGER | |||
| HMV-II | Growth Inhibition Assay | IC50=15.3333 μM | SANGER | |||
| COLO-679 | Growth Inhibition Assay | IC50=15.501 μM | SANGER | |||
| JAR | Growth Inhibition Assay | IC50=15.7205 μM | SANGER | |||
| NCI-H1666 | Growth Inhibition Assay | IC50=15.9399 μM | SANGER | |||
| SW48 | Growth Inhibition Assay | IC50=15.9516 μM | SANGER | |||
| NCI-H720 | Growth Inhibition Assay | IC50=15.9989 μM | SANGER | |||
| HT-1197 | Growth Inhibition Assay | IC50=16.0352 μM | SANGER | |||
| HL-60 | Growth Inhibition Assay | IC50=16.0384 μM | SANGER | |||
| BEN | Growth Inhibition Assay | IC50=16.5638 μM | SANGER | |||
| HAL-01 | Growth Inhibition Assay | IC50=16.8909 μM | SANGER | |||
| SW900 | Growth Inhibition Assay | IC50=16.9132 μM | SANGER | |||
| SBC-1 | Growth Inhibition Assay | IC50=17.5429 μM | SANGER | |||
| SH-4 | Growth Inhibition Assay | IC50=17.5841 μM | SANGER | |||
| UACC-62 | Growth Inhibition Assay | IC50=17.7637 μM | SANGER | |||
| BHT-101 | Growth Inhibition Assay | IC50=19.8705 μM | SANGER | |||
| DB | Growth Inhibition Assay | IC50=21.5649 μM | SANGER | |||
| SK-MEL-1 | Growth Inhibition Assay | IC50=21.5872 μM | SANGER | |||
| NCI-H747 | Growth Inhibition Assay | IC50=22.7379 μM | SANGER | |||
| SK-LU-1 | Growth Inhibition Assay | IC50=23.3524 μM | SANGER | |||
| KG-1 | Growth Inhibition Assay | IC50=23.4946 μM | SANGER | |||
| LXF-289 | Growth Inhibition Assay | IC50=23.714 μM | SANGER | |||
| HCC1954 | Growth Inhibition Assay | IC50=24.8844 μM | SANGER | |||
| Ramos-2G6-4C10 | Growth Inhibition Assay | IC50=26.4981 μM | SANGER | |||
| DBTRG-05MG | Growth Inhibition Assay | IC50=26.6488 μM | SANGER | |||
| NCI-H2052 | Growth Inhibition Assay | IC50=27.5684 μM | SANGER | |||
| RMG-I | Growth Inhibition Assay | IC50=29.4139 μM | SANGER | |||
| H9 | Growth Inhibition Assay | IC50=31.3008 μM | SANGER | |||
| GR-ST | Growth Inhibition Assay | IC50=32.4453 μM | SANGER | |||
| Mo-T | Growth Inhibition Assay | IC50=32.5046 μM | SANGER | |||
| SW1088 | Growth Inhibition Assay | IC50=32.9801 μM | SANGER | |||
| LB2518-MEL | Growth Inhibition Assay | IC50=33.0797 μM | SANGER | |||
| NCI-H82 | Growth Inhibition Assay | IC50=33.1661 μM | SANGER | |||
| LAMA-84 | Growth Inhibition Assay | IC50=34.6073 μM | SANGER | |||
| KYSE-450 | Growth Inhibition Assay | IC50=34.6776 μM | SANGER | |||
| LU-99A | Growth Inhibition Assay | IC50=35.0007 μM | SANGER | |||
| BE-13 | Growth Inhibition Assay | IC50=35.6545 μM | SANGER | |||
| GAK | Growth Inhibition Assay | IC50=35.695 μM | SANGER | |||
| NCI-H1573 | Growth Inhibition Assay | IC50=35.8818 μM | SANGER | |||
| AsPC-1 | Growth Inhibition Assay | IC50=36.1527 μM | SANGER | |||
| HDLM-2 | Growth Inhibition Assay | IC50=36.316 μM | SANGER | |||
| NCI-H441 | Growth Inhibition Assay | IC50=37.0691 μM | SANGER | |||
| CAL-27 | Growth Inhibition Assay | IC50=37.7231 μM | SANGER | |||
| OVCAR-3 | Growth Inhibition Assay | IC50=39.3181 μM | SANGER | |||
| RPMI-8226 | Growth Inhibition Assay | IC50=39.598 μM | SANGER | |||
| EFO-21 | Growth Inhibition Assay | IC50=40.5814 μM | SANGER | |||
| SNU-C2B | Growth Inhibition Assay | IC50=41.5084 μM | SANGER | |||
| VM-CUB-1 | Growth Inhibition Assay | IC50=43.8037 μM | SANGER | |||
| NCI-H2087 | Growth Inhibition Assay | IC50=45.0233 μM | SANGER | |||
| EW-16 | Growth Inhibition Assay | IC50=46.3137 μM | SANGER | |||
| SK-N-AS | Growth Inhibition Assay | IC50=46.7167 μM | SANGER | |||
| COR-L105 | Growth Inhibition Assay | IC50=46.8857 μM | SANGER | |||
| DEL | Growth Inhibition Assay | IC50=48.0429 μM | SANGER | |||
| JVM-2 | Growth Inhibition Assay | IC50=48.0558 μM | SANGER | |||
| KARPAS-45 | Growth Inhibition Assay | IC50=49.4538 μM | SANGER | |||
| BL21 (DE3) | Function assay | Binding affinity to human recombinant Mdm2 T101W mutant expressed in Escherichia coli BL21 (DE3) cells by antagonist induced dissociation assay, Kd = 0.5 μM. | 18680271 | |||
| BL21 (DE3) | Function assay | Binding affinity to human recombinant Mdm2 K98W mutant expressed in Escherichia coli BL21 (DE3) cells by antagonist induced dissociation assay, Kd = 0.5 μM. | 18680271 | |||
| BL21 (DE3) | Function assay | Binding affinity to human recombinant Mdm2 F55W mutant expressed in Escherichia coli BL21 (DE3) cells by NMR ligand-protein binary titration, Kd = 0.5 μM. | 18680271 | |||
| SJSA1 | Antiproliferative assay | 3 days | Antiproliferative activity against human SJSA1 cells after 3 days by EdU incorporation assay in presence of 10% human serum, IC50 = 0.7 μM. | 22524527 | ||
| HCT116 | Function assay | 24 hrs | Induction of p53-Ser15 phosphorylation in human HCT116 cells after 24 hrs, IC50 = 1 μM. | 19856920 | ||
| BL21 (DE3) | Function assay | Binding affinity to human recombinant Mdm2 T101W mutant expressed in Escherichia coli BL21 (DE3) cells by NMR ligand-protein binary titration, Kd = 1 μM. | 18680271 | |||
| BL21 (DE3) | Function assay | Binding affinity to human recombinant Mdm2 K98W mutant expressed in Escherichia coli BL21 (DE3) cells by NMR ligand-protein binary titration, Kd = 1 μM. | 18680271 | |||
| SJSA1 | Cytotoxicity assay | Cytotoxicity against human SJSA1 cells, IC50 = 1 μM. | 25396320 | |||
| RKO | Cytotoxicity assay | Cytotoxicity against human RKO cells, IC50 = 1 μM. | 25396320 | |||
| HCT116 | Cytotoxicity assay | Cytotoxicity against human HCT116 cells, IC50 = 1 μM. | 25396320 | |||
| SJSA1 | Growth inhibition assay | Growth inhibition of human SJSA1 cells expressing MDM2 by SRB assay, GI50 = 1.3 μM. | 21875801 | |||
| HCT116 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human HCT116 cells expressing wild type p53 incubated for 72 hrs by MTS assay, IC50 = 1.3 μM. | 30221935 | ||
| HCT116 | Function assay | 8 hrs | Induction of p53 in human HCT116 cells coexpressing pp53TA-luc assessed as inhibition of cell proliferation after 8 hrs by firefly/renilla luciferase reporter assay, IC50 = 1.39 μM. | 19856920 | ||
| HGF | Cytotoxicity assay | 24 hrs | Cytotoxicity against human HGF cells after 24 hrs by MTT assay, IC50 = 1.4 μM. | 23802716 | ||
| SJSA1 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human SJSA1 cells expressing wild type p53 incubated for 72 hrs by MTS assay, IC50 = 1.44 μM. | 30221935 | ||
| SJSA1 | Cytotoxicity assay | 5 days | Cytotoxicity against human SJSA1 cells expressing wild type p53 assessed as cell viability after 5 days by MTT assay, IC50 = 1.5 μM. | 24900694 | ||
| RKO | Cytotoxicity assay | 5 days | Cytotoxicity against human RKO cells expressing wild type p53 assessed as cell viability after 5 days by MTT assay, IC50 = 1.5 μM. | 24900694 | ||
| HCT116 | Cytotoxicity assay | 5 days | Cytotoxicity against human HCT116 cells expressing wild type p53 assessed as cell viability after 5 days by MTT assay, IC50 = 1.5 μM. | 24900694 | ||
| A2780 | Growth inhibition assay | Growth inhibition of human A2780 cells expressing MDM2 by SRB assay, GI50 = 1.6 μM. | 21875801 | |||
| HCT116 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HCT116 cells after 72 hrs by CellTiterGlo luciferase-based assay, IC50 = 1.6 μM. | 24139845 | ||
| SJSA1 | Antiproliferative assay | Antiproliferative activity against human SJSA1 cells, IC50 = 1.9 μM. | 24656661 | |||
| SJSA1 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human SJSA1 cells expressing wild type p53 after 72 hrs by CellTitre-Glo assay, IC50 = 1.9 μM. | 26985323 | ||
| HCT116 | Growth inhibition assay | Growth inhibition of human HCT116 cells expressing MDM2 by SRB assay, GI50 = 2.1 μM. | 21875801 | |||
| NGP | Cytotoxicity assay | 72 hrs | Cytotoxicity against human NGP cells after 72 hrs by sulforhodamine B assay, GI50 = 2.1 μM. | 21314128 | ||
| LS | Cytotoxicity assay | 72 hrs | Cytotoxicity against human LS cells after 72 hrs by sulforhodamine B assay, GI50 = 2.3 μM. | 21314128 | ||
| SJSA1 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human SJSA1 cells after 72 hrs by sulforhodamine B assay, GI50 = 2.6 μM. | 21314128 | ||
| MCF7 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay, IC50 = 2.9 μM. | 23802716 | ||
| HCT116 | Antiproliferative assay | 72 hrs | Antiproliferative activity in p53 (+/+) human HCT116 cells incubated for 72 hrs by MTS assay, IC50 = 4 μM. | 28987608 | ||
| A549 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human A549 cells expressing wild type p53 assessed as growth inhibition after 72 hrs by SRB assay, IC50 = 4.62 μM. | 23601819 | ||
| A549 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human A549 cells expressing wild type p53 after 72 hrs by SRB assay, IC50 = 4.62 μM. | 23611770 | ||
| MCF7 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay, IC50 = 5.01 μM. | 27101893 | ||
| HepG2 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay, IC50 = 5.1 μM. | 25479770 | ||
| HCT116 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human HCT116 cells expressing wild type p53 assessed as growth inhibition after 72 hrs by MTT assay, IC50 = 5.21 μM. | 27101893 | ||
| UKF-NB-3 | Cytotoxicity assay | 96 hrs | Cytotoxicity against doxorubicin-resistant human UKF-NB-3 cells after 96 hrs by MTT assay, IC50 = 5.56 μM. | 20947617 | ||
| SJSA1 | Function assay | 7 hrs | Activity at p53 in human SJSA1 cells assessed as induction of p21 mRNA expression after 7 hrs by qRT-PCR analysis in presence of 10% human serum, IC50 = 7.1 μM. | 22524527 | ||
| HCT116 | Growth inhibition assay | 48 hrs | Growth inhibition of human HCT116 cells harboring p53+/+ after 48 hrs by Hoechst 33258 staining based fluorescence assay, GI50 = 8 μM. | 29089230 | ||
| MCF7 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human MCF7 cells after 72 hrs by CCK8 assay, IC50 = 8.5 μM. | 30045621 | ||
| HCT116 | Antiproliferative assay | 24 hrs | Antiproliferative activity against human HCT116 p53+/+ cells assessed as growth inhibition after 24 hrs by EdU/Hoechst 33342 staining-based fluorescence analysis, GI50 = 9 μM. | 29691156 | ||
| HCT116 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human HCT116 cells after 72 hrs by CCK8 assay, IC50 = 9.07 μM. | 30045621 | ||
| A549 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human A549 cells after 72 hrs by CCK8 assay, IC50 = 9.58 μM. | 30045621 | ||
| HepG2 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay, IC50 = 10.2 μM. | 23802716 | ||
| NCI-H1299 | Antiproliferative assay | 72 hrs | Antiproliferative activity against p53 -/- human NCI-H1299 cells incubated for 72 hrs by MTS assay, IC50 = 10.4 μM. | 30221935 | ||
| MCF7 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay, IC50 = 11.6 μM. | 25618595 | ||
| Saos2 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human p53-deficient Saos2 cells after 72 hrs by MTT assay, IC50 = 12.1 μM. | 22940704 | ||
| HCT116 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human p53 expressing HCT116 cells after 72 hrs by sulforhodamine B assay, GI50 = 13 μM. | 21314128 | ||
| U2OS | Antiproliferative assay | 72 hrs | Antiproliferative activity against human U2OS cells expressing wild type p53 after 72 hrs by MTT assay, IC50 = 14.31 μM. | 23046248 | ||
| H1299 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human H1299 cells after 72 hrs by CellTiterGlo luciferase-based assay, IC50 = 14.7 μM. | 24139845 | ||
| A549 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human A549 cells expressing wild type p53 after 72 hrs by MTT assay, IC50 = 15 μM. | 22940704 | ||
| A549 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human A549 cells expressing wild type p53 after 72 hrs by MTT assay, IC50 = 15.12 μM. | 23046248 | ||
| U937 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human U937 cells after 24 hrs by MTT assay, IC50 = 15.6 μM. | 23802716 | ||
| Saos2 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human Saos2 cells after 72 hrs by sulforhodamine B assay, GI50 = 18 μM. | 21314128 | ||
| U2OS | Antiproliferative assay | 72 hrs | Antiproliferative activity against human U2OS cells expressing wild type p53 after 72 hrs by MTT assay, IC50 = 19.6 μM. | 22940704 | ||
| NCI-H1299 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human NCI-H1299 cells after 72 hrs by CCK8 assay, IC50 = 19.76 μM. | 30045621 | ||
| PC3 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human p53-null PC3 cells assessed as growth inhibition after 72 hrs by SRB assay, IC50 = 20.04 μM. | 23601819 | ||
| PC3 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human p53 deficient PC3 cells after 72 hrs by SRB assay, IC50 = 20.04 μM. | 23611770 | ||
| A2780/CP70 | Growth inhibition assay | Growth inhibition of human A2780/CP70 cells expressing isogenically paired p53 mutant by SRB assay, GI50 = 20.4 μM. | 21875801 | |||
| NCI-H1299 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human p53-deficient NCI-H1299 cells after 72 hrs by MTT assay, IC50 = 20.4 μM. | 22940704 | ||
| NCI-H1299 | Antiproliferative assay | 72 hrs | Antiproliferative activity against p53 deficient human NCI-H1299 cells after 72 hrs by MTT assay, IC50 = 20.48 μM. | 23046248 | ||
| HCT116 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human p53-null HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay, IC50 = 21.5 μM. | 27101893 | ||
| SJSA1 | Cytotoxicity assay | 24 hrs | Cytotoxicity in human SJSA1 cells over expressing human DM2 after 24 hrs by CellTiter-Glo assay, EC50 = 22.8 μM. | 29150077 | ||
| C643 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human C643 cells after 24 hrs by MTT assay, IC50 = 23 μM. | 23802716 | ||
| MDA-MB-231 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay, IC50 = 23.5 μM. | 25618595 | ||
| U2OS | Antitumor assay | 72 hrs | Antitumor activity against human U2OS cells expressing wild type p53 after 72 hrs by MTT assay, IC50 = 24.61 μM. | 21996465 | ||
| HCT116 | Growth inhibition assay | Growth inhibition of p53 deficient human HCT116 cells expressing MDM2 by SRB assay, GI50 = 25.6 μM. | 21875801 | |||
| HCT116 | Growth inhibition assay | 48 hrs | Growth inhibition of human p53 knockdown HCT116 cells after 48 hrs by Hoechst 33258 staining based fluorescence assay, GI50 = 27 μM. | 29089230 | ||
| Calu | Cytotoxicity assay | 24 hrs | Cytotoxicity against human Calu cells after 24 hrs by MTT assay, IC50 = 27.2 μM. | 23802716 | ||
| HCT116 | Antiproliferative assay | 24 hrs | Antiproliferative activity against human HCT116 p53-/- cells assessed as growth inhibition after 24 hrs by EdU/Hoechst 33342 staining-based fluorescence analysis, GI50 = 29 μM. | 29691156 | ||
| MDA-MB-435S | Antiproliferative assay | 72 hrs | Antiproliferative activity against human MDA-MB-435S cells assessed as growth inhibition after 72 hrs by MTT assay, IC50 = 29.6 μM. | 27101893 | ||
| PC3 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human PC3 cells after 24 hrs by MTT assay, IC50 = 30.3 μM. | 23802716 | ||
| Saos2 | Antiproliferative assay | 72 hrs | Antiproliferative activity against p53 deficient human Saos2 cells after 72 hrs by MTT assay, IC50 = 31.62 μM. | 23046248 | ||
| HCT116 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human HCT116 cells expressing wild type p53 after 48 hrs by MTT assay, GI50 = 32.11 μM. | 24852275 | ||
| HCT116 | Cytotoxicity assay | 72 hrs | Cytotoxicity against p53 deficient human HCT116 cells after 72 hrs by sulforhodamine B assay, GI50 = 34 μM. | 21314128 | ||
| HCT116 | Antiproliferative assay | 24 hrs | Antiproliferative activity against human HCT116 cells expressing p53 after 24 hrs by MTS assay, GI50 = 39.65 μM. | 24268795 | ||
| A549 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human A549 cells after 48 hrs by MTT assay, GI50 = 47.59 μM. | 24852275 | ||
| HCT116 | Antiproliferative assay | 72 hrs | Antiproliferative activity in p53 (-/-) human HCT116 cells incubated for 72 hrs by MTS assay, IC50 = 47.8 μM. | 28987608 | ||
| MCF7 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay, GI50 = 48.74 μM. | 24852275 | ||
| SJSA1 | Function assay | 10 uM | Inhibition of MDM2-p53 interaction in human SJSA1 cells assessed as p53 activation at 10 uM by Western blot | 19928922 | ||
| MCF7 | Cell cycle assay | 4 uM | 14 days | Induction of cell cycle arrest in human MCF7 cells transfected with p53-targeting iRNA-based shRNA at 4 uM after 14 days by BrdU incorporation assay | 16474381 | |
| MCF7 | Cell cycle assay | 4 uM | 14 days | Induction of cell cycle arrest in human MCF7 cells transfected hnRNPK-targeting iRNA-based shRNA at 4 uM after 14 days by BrdU incorporation assay | 16474381 | |
| MCF7 | Antiproliferative assay | 4 uM | 14 days | Antiproliferative activity against human MCF7 cells at 4 uM after 14 days by coomassie staining | 16474381 | |
| MCF7 | Antiproliferative assay | 4 uM | 14 days | Antiproliferative activity against human MCF7 cells assessed as appearance of flattened phenotype at 4 uM after 14 days by coomassie staining | 16474381 | |
| MCF7 | Function assay | Induction of p53 expression in human MCF7 cells transfected with 53BP1-targeting iRNA-based shRNA by Western blot analysis | 16474381 | |||
| MCF7 | Function assay | Induction of p53 expression in human MCF7 cells by Western blot analysis | 16474381 | |||
| MCF7 | Function assay | 18 hrs | Induction of p53 accumulation in human MCF7 cells after 18 hrs by Western blot analysis in presence of 2.5 mM caffeine | 16474381 | ||
| BJ | Function assay | 3 uM | Induction of p21CIP1 expression in irradiated human BJ cells at 3 uM by Western blot analysis | 16474381 | ||
| MCF7 | Cell cycle assay | 4 uM | 14 days | Induction of cell cycle arrest in human MCF7 cells transfected with 53BP1-targeting iRNA-based shRNA at 4 uM after 14 days by BrdU incorporation assay | 16474381 | |
| BJ | Function assay | 3 uM | Induction of p21 expression in irradiated human BJ cells at 3 uM by Western blot analysis | 16474381 | ||
| SNJSA1 | Function assay | 1 to 10 uM | 6 hrs | Inhibition of Mdm2 -p53 protein interaction in human SNJSA1 cells assessed as induction of p21 protein at 1 to 10 uM after 6 hrs by Western blot analysis | 21314128 | |
| SNJSA1 | Function assay | 1 to 10 uM | 6 hrs | Inhibition of Mdm2 -p53 protein interaction in human SNJSA1 cells assessed as induction of p53 protein at 1 to 10 uM after 6 hrs by Western blot analysis | 21314128 | |
| SNJSA1 | Function assay | 1 to 10 uM | 6 hrs | Inhibition of Mdm2 -p53 protein interaction in human SNJSA1 cells assessed as induction of MDM2 protein at 1 to 10 uM after 6 hrs by Western blot analysis | 21314128 | |
| MCF7 | Function assay | 24 hrs | Upregulation of p53 in human MCF7 cells after 24 hrs by Western blot analysis | 27010502 | ||
| MCF7 | Function assay | 24 hrs | Upregulation of Mdm2 in human MCF7 cells after 24 hrs by Western blot analysis | 27010502 | ||
| MCF7 | Function assay | 24 hrs | Increase in p53 expression in human MCF7 cells nuclei after 24 hrs by DAPI staining based immunofluorescence microscopy | 27010502 | ||
| MCF7 | Function assay | 24 hrs | Upregulation of p21 in human MCF7 cells after 24 hrs by Western blot analysis | 27010502 | ||
| HCT116 | Function assay | 50 uM | 24 hrs | Inhibition of p53-MDM2 (unknown origin) interaction expressed in p53-deficient human HCT116 cells at 50 uM after 24 hrs by BiFC-based FACS flow cytometric analysis | 24268795 | |
| U2OS | Function assay | 2.5 uM | 12 hrs | Stabilization of p53 in human U2OS cells assessed as intracellular p53 level at 2.5 uM after 12 hrs by Western blotting | 26288684 | |
| HCT116 | Function assay | 10 uM | 20 hrs | Inhibition of V1-p53/MDM2-V2 (unknown origin) interaction expressed in human HCT116 p53-/- cells at 10 uM after 20 hrs by biomolecular fluorescence complementation-based flow cytometric analysis | 28800455 | |
| IMR32 | Function assay | 24 hrs | Increase in p53 expression in human IMR32 cells nuclei after 24 hrs by DAPI staining based immunofluorescence microscopy | 27010502 | ||
| MCF7 | Function assay | 10 uM | 16 hrs | Inhibition of MDM2-p53 interaction in human MCF7 cells assessed as reversal of MDM2-dependent inhibition of p53-induced transcriptional activity at 10 uM after 16 hrs by dual-luciferase reporter gene assay | 23540934 | |
| MCF7 | Apoptosis assay | 3 uM | 24 to 72 hrs | Induction of apoptosis in human MCF7 cells assessed as reduction in Bcl-xL expression level at 3 uM after 24 to 72 hrs by Western blotting analysis | 23802716 | |
| MCF7 | Apoptosis assay | 3 uM | 24 to 72 hrs | Induction of apoptosis in human MCF7 cells assessed as early apoptotic cells at 3 uM after 24 to 72 hrs by annexin V-FITC/propidium iodide staining based FACS flow cytometry (Rvb = 4 %) | 23802716 | |
| MCF7 | Apoptosis assay | 3 uM | 24 to 72 hrs | Induction of apoptosis in human MCF7 cells assessed as increase in p21 expression level at 3 uM after 24 to 72 hrs by Western blotting analysis | 23802716 | |
| MCF7 | Apoptosis assay | 3 uM | 24 to 72 hrs | Induction of apoptosis in human MCF7 cells assessed as increase in Bcl-xS expression level at 3 uM after 24 to 72 hrs by Western blotting analysis | 23802716 | |
| MCF7 | Apoptosis assay | 50 nM | 24 to 72 hrs | Induction of apoptosis in human MCF7 cells assessed as accumulation of caspase-3 cleavage product at 50 nM after 24 to 72 hrs by Western blotting analysis | 23802716 | |
| MCF7 | Cell cycle assay | 3 uM | 24 to 72 hrs | Cell cycle arrest in human MCF7 cells assessed as accumulation at G0/G1 phase at 3 uM after 24 to 72 hrs by propidium iodide staining-based FACS analysis | 23802716 | |
| Klicken Sie hier, um weitere experimentelle Daten zu Zelllinien anzuzeigen | ||||||
| Molekulargewicht | 581.49 | Formel | C30H30Cl2N4O4 |
Lagerung (Ab dem Eingangsdatum) | |
|---|---|---|---|---|---|
| CAS-Nr. | 675576-98-4 | -- | Lagerung von Stammlösungen |
|
|
| Synonyme | (-)-Nutlin-3 | Smiles | CC(C)OC1=C(C=CC(=C1)OC)C2=NC(C(N2C(=O)N3CCNC(=O)C3)C4=CC=C(C=C4)Cl)C5=CC=C(C=C5)Cl | ||
|
In vitro |
DMSO
: 100 mg/mL
(171.97 mM)
Ethanol : 100 mg/mL Water : Insoluble |
|
In vivo |
|||||
Schritt 1: Geben Sie die untenstehenden Informationen ein (Empfohlen: Ein zusätzliches Tier zur Berücksichtigung von Verlusten während des Experiments)
Schritt 2: Geben Sie die In-vivo-Formulierung ein (Dies ist nur der Rechner, keine Formulierung. Bitte kontaktieren Sie uns zuerst, wenn es im Abschnitt "Löslichkeit" keine In-vivo-Formulierung gibt.)
Berechnungsergebnisse:
Arbeitskonzentration: mg/ml;
Methode zur Herstellung der DMSO-Stammlösung: mg Wirkstoff vorgelöst in μL DMSO ( Konzentration der Stammlösung mg/mL, Bitte kontaktieren Sie uns zuerst, wenn die Konzentration die DMSO-Löslichkeit der Wirkstoffcharge überschreitet. )
Methode zur Herstellung der In-vivo-Formulierung: Nehmen Sie μL DMSO Stammlösung, dann hinzufügenμL PEG300, mischen und klären, dann hinzufügenμL Tween 80, mischen und klären, dann hinzufügen μL ddH2O, mischen und klären.
Methode zur Herstellung der In-vivo-Formulierung: Nehmen Sie μL DMSO Stammlösung, dann hinzufügen μL Maisöl, mischen und klären.
Hinweis: 1. Bitte stellen Sie sicher, dass die Flüssigkeit klar ist, bevor Sie das nächste Lösungsmittel hinzufügen.
2. Achten Sie darauf, das/die Lösungsmittel der Reihe nach hinzuzufügen. Sie müssen sicherstellen, dass die bei der vorherigen Zugabe erhaltene Lösung eine klare Lösung ist, bevor Sie mit der Zugabe des nächsten Lösungsmittels fortfahren. Physikalische Methoden wie Vortex, Ultraschall oder ein heißes Wasserbad können zur Unterstützung des Lösens verwendet werden.
| Merkmale |
Highly selective MDM2 inhibitor with a much lower effect on MDMX. Most effective on tumors with wild type p53.
|
|---|---|
| Targets/IC50/Ki |
p53-MDM2 interaction
(Cell-free assay) 90 nM
|
| In vitro |
Nutlin-3a verdrängt p53 aus der Bindungstasche von MDM2 und setzt dadurch p53 von Hemmung und proteasomalem Abbau frei, was zur Induktion seiner nachgeschalteten Ziele, Zellzyklusarrest und Apoptosis führt. Sieben Tage Inkubation mit 10 μM dieser Verbindung führten zu >90% Hemmung des Wachstums von NIH3T3-Zellen. Diese Verbindung stabilisiert und aktiviert p53 und induziert die p21-Expression dosisabhängig. Sie reduziert effektiv das S-Phasen-Kompartiment auf 0,2-2% und erhöht die G1- und G2/M-Phasen-Kompartimente. Diese Chemikalie induziert Apoptosis bei ~60% der SJSA-1- und MHM
Zellen nach 40 h, was nach 60 h weiter anstieg (85% bzw. 65%) .
|
| Kinase-Assay |
Biacore-Studien
|
|
Kompetitionsassays werden auf einem Biacore S51 durchgeführt. Ein Sensorchip CM5 der Serie S wird für die Immobilisierung eines PentaHis-Antikörpers zur Erfassung des His-markierten p53 derivatisiert. Der Erfassungsgrad beträgt ~200 Response Units (1 Response Unit entspricht 1 pg Protein pro mm2). Die Konzentration des MDM2-Proteins wird konstant bei 300 nM gehalten. Testsubstanzen werden in DMSO bei 10 mM gelöst und weiter verdünnt, um eine Konzentrationsreihe des Inhibitors in jeder MDM2-Testprobe herzustellen. Die Assays werden bei 25 °C in Laufpuffer (10 mM Hepes, 0,15 M NaCl, 2% DMSO) durchgeführt. Die MDM2-p53-Bindung in Anwesenheit dieser Verbindung wird als Prozentsatz der Bindung in Abwesenheit dieser Verbindung berechnet, und die IC50 wird mit Microsoft Excel berechnet.
|
|
| In vivo |
Nutlin-3a unterdrückt das Xenograft-Wachstum dosisabhängig, wobei die höchste Dosis (200 mg/kg) eine erhebliche Tumorschrumpfung zeigte . Diese Verbindung ist ein selektiver Aktivator des p53-Signalwegs in vivo und hochwirksam gegen SJSA-1-Osteosarkom-Tumoren. Tumoren mit Wildtyp-p53 und MDM2-Genamplifikation sprechen am besten auf eine Therapie mit dieser Chemikalie an.
|
Literatur |
|
| Methoden | Biomarker | Bilder | PMID |
|---|---|---|---|
| Western blot | p53 / MDM2 / p21 / Bax / Bak / Noxa / cleaved caspase / pro-caspase BMI-1 p53-Ser15 / p53-Ser37 / p53-Lys382 / MDM2 / CDC2 / PLK1 / HSC70 |
|
16014563 |
| Immunofluorescence | p-p21 / β-actin P53 Ac-p300 |
|
31083332 |
| Growth inhibition assay | Cell viability |
|
26248031 |
Tel: +1-832-582-8158 Ext:3
Wenn Sie weitere Fragen haben, hinterlassen Sie bitte eine Nachricht.
Frage 1:
What is the difference between S1061 (Nutlin-3) and it?
Antwort:
S1061 is a racemic mixture of Nutlin3a and Nutlin3b. Its active enantiomer is s8059.